GSK plc
Search results
AstraZeneca is a global, science-led biopharmaceutical business and our innovative medicines are used by millions of patients worldwide.
- Careers
A.Catalyst Network is an interconnected and dynamic global...
- Investor Relations
Investor Relations - AstraZeneca - Research-Based...
- What science can do
What science can do - AstraZeneca - Research-Based...
- R&D
R&D - AstraZeneca - Research-Based BioPharmaceutical Company
- Our therapy areas
Our therapy areas - AstraZeneca - Research-Based...
- Our company
Our company. We are a global, science-led, patient-focused...
- Media
Media - AstraZeneca - Research-Based BioPharmaceutical...
- Sustainability
Sustainability - AstraZeneca - Research-Based...
- Careers
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
It has its research and development concentrated in three strategic centres: Cambridge, England; Gothenburg, Sweden and Gaithersburg in Maryland, U.S. [9] AstraZeneca traces its earliest corporate history to 1913, when Astra AB was formed by a large group of doctors and apothecaries in Södertälje.
Our company. We are a global, science-led, patient-focused pharmaceutical company. We are dedicated to transforming the future of healthcare by unlocking the power of what science can do for people, society and the planet.
- Who Can Be Vaccinated?
- Should Pregnant and Breastfeeding Women Be Vaccinated?
- Who Is The Vaccine Not Recommended for?
- Is It Safe?
- How Efficacious Is The Vaccine?
- What Is The Recommended Dosage?
- Is A Booster Dose Recommended For This Vaccine?
- Can This Vaccine Be ‘Mixed and Matched’ with Other Vaccines?
- Does It Prevent Infection and Transmission?
- Does It Work Against New Variants?
The vaccine is safe and effective for all individuals aged 18 and above. In line with the WHO Prioritization Roadmap and and the WHO Values Frameworkolder adults, health workers and immunocompromised persons should be prioritised. The Astra-Zeneca vaccine can be offered to people who have had COVID-19 in the past. But individuals may choose to dela...
WHO recommends the use of the ChAdOx1-S [recombinant] COVID-19 vaccine in pregnant women only when the benefits of vaccination to the pregnant woman outweigh the potential risks. To help pregnant women make this assessment, they should be provided with information about the risks of COVID-19 in pregnancy, the likely benefits of vaccination in the l...
People with a history of severe allergic reaction to any component of the vaccine should not take it. The vaccine is not recommended for persons younger than 18 years of age pending the results of further studies.
The Global Advisory Committee on Vaccine Safety, a group of experts that provides independent and authoritative guidance to the WHO on the topic of safe vaccine use, receives and assesses reports of suspected safety events of potentially international impact. A very rare adverse event called Thrombosis with Thrombocytopenia Syndrome (TTS), involvin...
The AstraZeneca vaccine has an efficacy of 72% against symptomatic SARS-CoV-2 infection, as shown by the primary analysis of data irrespective of interdose interval from trial participants who received 2 standard doses with an interval varying from about 4 to 12 weeks. Vaccine efficacy tended to be higher when the interval between doses was longer.
The recommended dosage is two doses given intramuscularly (0.5ml each) with an interval of 8 to 12 weeks. For countries that have not yet achieved high vaccine coverage rates in the high-priority groups and that are experiencing high incidence of COVID-19 cases combined with vaccine supply constraints, longer intervals i.e. up to 16 weeks can be co...
A booster dose may be considered 4 – 6 months after completion of the primary vaccination series, starting with the higher priority-use groups, in accordance with the WHO Prioritization Roadmap. The benefits of booster vaccination are recognized following increasing evidence of waning vaccine effectiveness against mild and asymptomatic SARS-CoV-2 i...
SAGE accepts two heterologous doses of WHO EUL COVID-19 vaccines as a complete primary series. For countries considering heterologous schedules, WHO has made recommendations to ensure equivalent or favourable immunogenicity or vaccine effectiveness for heterologous versus homologous schedules: 1. The Astra-Zeneca vaccine recommendations have also b...
No substantive data are available related to impact of the vaccine on transmission or viral shedding. In the meantime, we must maintain and strengthen public health and social measures that work: masking, physical distancing, handwashing, respiratory and cough hygiene, avoiding crowds, and ensuring good ventilation.
SAGE has reviewed all available data on the performance of the vaccine in the settings of variants of concern. SAGE currently recommends its use according to the WHO Prioritization Roadmap, even if virus variants are present in a country. Countries should assess the risks and benefits taking into consideration their epidemiological situation. Preli...
Apr 23, 2021 · Vaxzevria (formerly COVID-19 Vaccine AstraZeneca) is authorised in the EU to prevent COVID-19, which can cause severe disease and death. The disease can also have long-term consequences in people of all ages, including in otherwise healthy people.
Mar 22, 2021 · Results from the long-awaited US trial of the Oxford-AstraZeneca Covid vaccine are out and confirm that the shot is both safe and highly effective.
